The results of our study are in line with the results of other studies that also reported a decrease in IR in diabetic individuals with silymarin administration as an adjunct to standard insulin therapy for T2DM [65,67,69] or in diabetic individuals with cirrhosis [62,63]. This evidence concerns the gene INS and type 2 diabetes mellitus.